Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Love, Thorvardur Jon
Reed, Elín Ruth
Óskarsson, Jón Þórir
Sigurðardóttir, Guðrún Ásta
Önundarson, Páll Torfi
Agnarsson, Bjarni A
Þórðardóttir, Ásdís Rósa
Björnsson, Andri S
Gunnarsson, Gunnar Þór
Indriðason, Ólafur Skúli
Gíslason, Gauti Kjartan
Hákonardóttir, Guðlaug Katrín
Halldórsdóttir, Sara Lovísa
Ásgeirsdóttir, Tinna Laufey
Dröfn Wessman, Inga
Durie, Brian G M
Kristinsson, Sigurður Yngvi
MetadataShow full item record
CitationRögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Eyþórsson E, Jónsson Á, Björnsson AS, Gunnarsson GÞ, Pálsson R, Indriðason ÓS, Gíslason GK, Ólafsson A, Hákonardóttir GK, Brinkhuis M, Halldórsdóttir SL, Ásgeirsdóttir TL, Steingrímsdóttir H, Danielsen R, Dröfn Wessman I, Kampanis P, Hulcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021 May 17;11(5):94. doi: 10.1038/s41408-021-00480-w.
AbstractMonoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
- Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
- Authors: Rognvaldsson S, Eythorsson E, Thorsteinsdottir S, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Thorsteinsdóttir I, Olafsson I, Runolfsdottir HL, Helgason D, Emilsdottir AR, Agustsson AS, Bjornsson AH, Kristjansdottir G, Thordardottir AR, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Steingrimsdottir H, Kampanis P, Hultcrantz M, Durie BGM, Harding S, Landgren O, Palsson R, Love TJ, Kristinsson SY
- Issue date: 2021 Dec 1
- The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
- Authors: Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY
- Issue date: 2015 May
- Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
- Authors: Altrock PM, Ferlic J, Galla T, Tomasson MH, Michor F
- Issue date: 2018 Dec
- Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
- Authors: Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM, Rajkumar SV
- Issue date: 2011 Sep 15
- [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
- Authors: Stelmach-Gołdyś A, Czarkowska-Paczek B
- Issue date: 2012